<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are at high risk for developing <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Evidence-based treatment recommendations with respect to the specific benefits or possible hazards of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> treatment are scarce </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: In a systematic search we only identified randomized, controlled trials for <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Further evidence is largely based on subgroup analyses of larger intervention studies in mostly systolic <z:hpo ids='HP_0001635'>heart failure</z:hpo>, on observational studies, or on registries </plain></SENT>
<SENT sid="4" pm="."><plain>Acknowledging this lack of data, <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> should be treated to appropriate guideline-recommended targets and <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> avoided until this evidence becomes available </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> should not be used because of an increased event rate in diabetic patients with established <z:hpo ids='HP_0001635'>heart failure</z:hpo> and a large increase in incident <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering strategies might be used in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001635'>heart failure</z:hpo>, but specific precautions must be considered </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The documented lack of data calls for specific trials, as <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> as well as their co-morbidities are highly prevalent and are becoming even more important with an increasing prevalence of <z:hpo ids='HP_0001513'>obesity</z:hpo> and an ageing population </plain></SENT>
</text></document>